Genor Biopharma Holdings Ltd. has announced advancements in the clinical evaluation of GB261, a novel T-cell engager. Candid Therapeutics, Inc., the licensee of GB261, has initiated clinical trials targeting autoimmune diseases, with the first patients having been dosed and reportedly tolerating the treatment well. The company has also established a subcutaneous dosing formulation for GB261. This bispecific antibody is designed to target CD20 on B-cells and CD3 on T-cells, aiming to mediate cytotoxicity against CD20-expressing B-cells while minimizing excessive T-cell activation. A phase I/II open-label multi-center study for relapsed/refractory B-cell non-Hodgkin's lymphoma has been completed in China and Australia. There is no assurance provided regarding the successful development and marketing of GB261.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.